Gain Client Recognition Again! Medicilon won the 2023 SicaGene "Best Partner Award"

Recently, Shanghai Medicilon Inc. (Medicilon) won the "Best Partner Award" from SicaGene. The strong support provided in collaboration projects has been recognized by client again.

Medicilon and SicaGene: Go Deep Alone, Go Far Together

The collaboration stems from a shared vision in the field of nucleic acid drugs. Antisense oligonucleotide drugs can break through the "undruggable targets" limitations of traditional small molecule drugs, but they also have extremely high technical barriers and development difficulties. As one of the first China innovative pharmaceutical companies to enter the ASO field, SicaGene has independently developed and constructed core technology platforms such as SicaScreenTM、SicaChemistryTM、SicaDeliveryTM , focusing on drug development in the fields of cardiovascular disease, viruses, and ophthalmology. SicaGene has also achieved efficient development of ASO drugs with high activity, low dosage, long administration cycle, good clinical tolerance and controllable cost.

It is also Medicilon's vision to improve the druggability and R&D efficiency of nucleic acid drugs and help nucleic acid drugs benefit the world. To this end, Medicilon relies on the Nucleic Acid Drug R&D Service Platform to empower SicaGene's ASO drug research and development, and the trust and support from SicaGene also encourage Medicilon to continue to innovate and improve. Through close collaboration between the two parties, the collaboration has achieved positive progress and phased results.

Nucleic Acid Drug R&D Service Platform provides one-stop support for R&D

Medicilon's Nucleic Acid Drug R&D Service Platform is an integrated and comprehensive platform that integrates drug discovery, production and preclinical research. Based on a rigorous scientific attitude, an open technology platform and advanced instruments and equipment, Medicilon can provide nucleic acid drug discovery, screening and preclinical research services to pharmaceutical companies and scientific research institutions.

Medicilon will continue to target cutting-edge tracks such as nucleic acid, cell and gene therapy, PROTAC, and ADC, strengthen technological innovation, and gather superior resources to provide clients with a one-stop biopharmaceutical preclinical R&D service platform and to empower global partners to accelerate pharmaceutical innovation.

此博客中的热门博文

What is preclinical testing?

In the process of preclinical testing of a compound or biological agent into a drug, the compound involved must go through the testing phase. First, we need to identify potential targets that can treat the disease. Then, a variety of compounds or preparations are screened out. Any compound that has shown potential as a drug for the treatment of this disease needs to be tested for toxicity before clinical testing to reduce the possibility of injury. preclinical testing What is the basis of preclinical testing? According to US Food and Drug Administration (FDA) regulations, a series of tests are required before a new drug is approved for use. In the first stage, basic research determines a hypothetical target for the treatment of a certain disease, and then screens small molecules or biological compounds to discover any substance with the potential to treat the disease. Then, a preclinical research phase followed, before which, as described above, the potential toxicity of the compou

阅读全文

Inventory of the three major in vitro pharmacokinetic research methods

The metabolic properties of a compound are an essential factor in whether or not it can be used as a drug in the clinical setting, so pharmacokinetic studies of newly synthesized compounds are required in drug development. In vitro incubation with liver microsomes, recombinant CYP450 enzyme lines, and in vitro incubation with hepatocytes are some of the more common in vitro drug metabolism methods. 1. In vitro incubation method with liver microsomes The metabolic stability and metabolic phenotypes of candidate compounds in different species of liver microsomes are good predictors of the metabolic properties of compounds in vivo. They are practical tools for evaluating candidate compounds in the pre-development phase of drug development. Liver microsomes include rat liver microsomes, human liver microsomes, canine liver microsomes, monkey liver microsomes, and mouse liver microsomes. In in vitro incubation of the liver, microsomes are the "gold standard" for in vitro d

阅读全文

Novel Parkinson’s Therapies Possible with New Mouse Model

Parkinson's disease (PD) is a neurodegenerative disorder that is marked by the accumulation of the protein, α-synuclein (αS), into clumps known as Lewy bodies, which diminish neural health. Now, researchers from Brigham and Women's Hospital (BWH) report the development of a mouse model to induce PD-like αS aggregation, leading to resting tremor and abnormal movement control. The mouse responds to L-DOPA, similarly to patients with PD. The team's study (“Abrogating Native α-Synuclein Tetramers in Mice Causes a L-DOPA-Responsive Motor Syndrome Closely Resembling Parkinson’s Disease”) on the use of this transgenic mouse model appears in Neuron . “α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in PD. Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutati

阅读全文

Shanghai Medicilon Inc.

搜索此博客